Tests keyhole stomach surgery that keeps or removes one vagus nerve branch
Compares two keyhole stomach-removal methods in adults with early upper gastric cancer.
Plain-language title generated from the registry record
Registry title: Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
Key facts
- Where
- Fuzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early gastric cancer in the upper part of the stomach, who are about to have laparoscopic surgery to remove the upper stomach.
- Age
- 18 to 75 years
- Sex
- Men and women can join
- Disease stage
- Gastric or esophagogastric junction adenocarcinoma in the upper third of the stomach, clinical stage cT1bN0M0 without lymph node spread. Esophagogastric junction tumors must be 4 cm (1.6 in) or smaller.
- Earlier treatment
- No earlier chemotherapy, radiotherapy, targeted therapy or immunotherapy. No earlier upper abdominal surgery, except laparoscopic cholecystectomy.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Another cancer within the last 5 years
- Severe lung, liver or kidney disease
- Heart attack, unstable angina, stroke or brain bleeding within 6 months
- Bleeding, perforation or blockage caused by the stomach cancer
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07142122, who can take part
Where in China
- 420 Fuma Road, Jin'an District, Fuzhou City, Fujian ProvinceFuzhou, ChinaContact: Zaisheng Ye, doctoralTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fujian Cancer Hospital
- Trial code
- NCT07142122
- Record updated
- 26 August 2025
- Original description
This prospective, single-center, randomized, controlled, non-inferiority clinical trial aims to compare the safety and postoperative quality of life of early upper gastric cancer patients undergoing total laparoscopic proximal gastrectomy (TLPG) with preservation of both the hepatic and celiac branches of the vagus nerve versus preservation of the hepatic branch only. The primary endpoint is gastric emptying half-time of solid food at 6 months after surgery. Secondary outcomes include incidence of reflux esophagitis, quality of life scores (EORTC QLQ-C30/STO22), number and positivity rate of lymph nodes retrieved, and 3-year disease-free survival. The study will provide evidence for optimizing minimally invasive surgical strategies for early upper gastric cancer.Read full original descriptionShow less
Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
This prospective, single-center, randomized, controlled, non-inferiority clinical trial aims to compare the safety and postoperative quality of life of early upper gastric cancer patients undergoing total laparoscopic proximal gastrectomy (TLPG) with preservation of both the hepatic and celiac branches of the vagus nerve versus preservation of the hepatic branch only. The primary endpoint is gastric emptying half-time of solid food at 6 months after surgery. Secondary outcomes include incidence of reflux esophagitis, quality of life scores (EORTC QLQ-C30/STO22), number and positivity rate of lymph nodes retrieved, and 3-year disease-free survival. The study will provide evidence for optimizing minimally invasive surgical strategies for early upper gastric cancer.
Inclusion: Age 18-75 years; Histologically confirmed gastric adenocarcinoma or esophagogastric junction adenocarcinoma (papillary, tubular, mucinous, poorly cohesive including signet-ring cell carcinoma, or mixed type); Primary tumor located in the upper third of the stomach, or esophagogastric junction cancer with tumor size ≤4 cm; Clinical stage cT1bN0M0 without lymph node metastasis; BMI <30 kg/m²; No history of upper abdominal surgery (except laparoscopic cholecystectomy); No prior chemotherapy, radiotherapy, targeted therapy, or immunotherapy; ECOG performance status 0-1; ASA class I-III; Adequate organ function; Signed informed consent.
Exclusion: Long-term systemic glucocorticoid therapy within 1 month (local use excluded); Other malignancies within 5 years; Active infection requiring systemic therapy or fever ≥38°C preoperatively; Severe psychiatric illness; Severe respiratory disease; Unstable angina or myocardial infarction within 6 months; Stroke or intracranial hemorrhage within 6 months; Complications of gastric cancer (bleeding, perforation, obstruction); Participation in another clinical study within 6 months; Exclusion During Study (Removal Criteria):; R0 resection not achieved, change of procedure to total gastrectomy or PPG, combined surgery for other diseases, severe perioperative complications, emergency surgery required, patient withdrawal of consent, or protocol violation; Pregnancy or breastfeeding; Severe hepatic or renal dysfunction.